Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib
It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafeni...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-12, Vol.15 (12), p.e0244293-e0244293 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0244293 |
|---|---|
| container_issue | 12 |
| container_start_page | e0244293 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Hsieh, Ming-Han Kao, Tzu-Yu Hsieh, Ting-Hui Kao, Chun-Chi Peng, Cheng-Yuan Lai, Hsueh-Chou Chuang, Po-Heng Kao, Jung-Ta |
| description | It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib.
From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to the presence/absence of DM or HTN, they were divided into four groups: control [DM(-)/HTN(-), n = 353], DM-only [DM(+)/HTN(-), n = 91], HTN-only [DM(-)/HTN(+), n = 184] and DM+HTN groups [DM(+)/HTN(+), n = 105]. Based on the types of diabetes medications, there were three groups among DM patients (the combined cohort of DM-only and DM+HTN groups), including metformin (n = 63), non-metformin oral hypoglycemic agent (OHA) (n = 104) and regular insulin (RI)/neutral protamine hagedorn (NPH) groups (n = 29). We then assessed the survival differences between these groups.
DM-only and DM+HTN groups significantly presented longer overall survival (OS) than control group (control vs. DM-only, 7.70 vs. 11.83 months, p = 0.003; control vs. DM+HTN, 7.70 vs. 11.43 months, p = 0.008). However, there was no significant OS difference between control and HTN-only group (7.70 vs. 8.80 months, p = 0.111). Besides, all groups of DM patients showed significantly longer OS than control group (control vs. metformin, 7.70 vs. 12.60 months, p = 0.011; control vs. non-metformin OHA, 7.70 vs. 10.80 months, p = 0.016; control vs. RI/NPH, 7.70 vs. 15.20 months, p = 0.026).
Rather than HTN, DM predicts better prognosis in advanced HCC treated with sorafenib. Besides, metformin, non-metformin OHA and RI/NPH are associated with longer survival among DM-related advanced HCC patients receiving sorafenib. |
| doi_str_mv | 10.1371/journal.pone.0244293 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2474469553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A647157301</galeid><doaj_id>oai_doaj_org_article_0c2fbbafc6e44ac193e0830ea91465ae</doaj_id><sourcerecordid>A647157301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-870fec631b8484dc751d961c33ace6cc61fae1a393f1257e32f4fe7fab2c572a3</originalsourceid><addsrcrecordid>eNqNk01v1DAQhiMEoqXwDxBEQkJw2MWOnTi5IFUVHytVKuLrak2c8a6rxN7aTqH_Hi-bVhvUA_LBlueZ157Xnix7TsmSMkHfXbrRW-iXW2dxSQrOi4Y9yI5pw4pFVRD28GB9lD0J4ZKQktVV9Tg7YozVhSDsOPNfvFtbF6JRuXc9htzpvDPQYkzrAfvexDHkYLt8c7NFH9EG42xubA7dNViFKYBbiE4lduzB5wq8MtYNkEePEBPwy8RNHpwHjda0T7NHGvqAz6b5JPvx8cP3s8-L84tPq7PT84WqmiIuakE0qorRtuY175QoaddUVDEGCiulKqoBKbCGaVqUAlmhuUahoS1UKQpgJ9nLve62d0FOdgVZcMF51ZQlS8RqT3QOLuXWmwH8jXRg5N8N59cSfHKmR0lUodsWtKqQc1DJWSQ1IwgN5VUJmLTeT6eN7YCdQhs99DPRecSajVy7aymEKElDksCbScC7qxFDlIMJO1PBohv39y4JobxO6Kt_0Purm6g1pAKM1S6dq3ai8rTigpaCEZqo5T1UGh0ORqW_pU3anyW8nSUkJuLvuIYxBLn69vX_2Yufc_b1AbtB6OMmuH6M6buFOcj3oPIuBI_6zmRK5K41bt2Qu9aQU2uktBeHD3SXdNsL7A_TWwvQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474469553</pqid></control><display><type>article</type><title>Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib</title><source>PubMed Central Free</source><source>MEDLINE</source><source>Public Library of Science</source><source>DOAJ Directory of Open Access Journals</source><source>Free Full-Text Journals in Chemistry</source><source>EZB Electronic Journals Library</source><creator>Hsieh, Ming-Han ; Kao, Tzu-Yu ; Hsieh, Ting-Hui ; Kao, Chun-Chi ; Peng, Cheng-Yuan ; Lai, Hsueh-Chou ; Chuang, Po-Heng ; Kao, Jung-Ta</creator><contributor>Yu, Ming-Lung</contributor><creatorcontrib>Hsieh, Ming-Han ; Kao, Tzu-Yu ; Hsieh, Ting-Hui ; Kao, Chun-Chi ; Peng, Cheng-Yuan ; Lai, Hsueh-Chou ; Chuang, Po-Heng ; Kao, Jung-Ta ; Yu, Ming-Lung</creatorcontrib><description>It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib.
From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to the presence/absence of DM or HTN, they were divided into four groups: control [DM(-)/HTN(-), n = 353], DM-only [DM(+)/HTN(-), n = 91], HTN-only [DM(-)/HTN(+), n = 184] and DM+HTN groups [DM(+)/HTN(+), n = 105]. Based on the types of diabetes medications, there were three groups among DM patients (the combined cohort of DM-only and DM+HTN groups), including metformin (n = 63), non-metformin oral hypoglycemic agent (OHA) (n = 104) and regular insulin (RI)/neutral protamine hagedorn (NPH) groups (n = 29). We then assessed the survival differences between these groups.
DM-only and DM+HTN groups significantly presented longer overall survival (OS) than control group (control vs. DM-only, 7.70 vs. 11.83 months, p = 0.003; control vs. DM+HTN, 7.70 vs. 11.43 months, p = 0.008). However, there was no significant OS difference between control and HTN-only group (7.70 vs. 8.80 months, p = 0.111). Besides, all groups of DM patients showed significantly longer OS than control group (control vs. metformin, 7.70 vs. 12.60 months, p = 0.011; control vs. non-metformin OHA, 7.70 vs. 10.80 months, p = 0.016; control vs. RI/NPH, 7.70 vs. 15.20 months, p = 0.026).
Rather than HTN, DM predicts better prognosis in advanced HCC treated with sorafenib. Besides, metformin, non-metformin OHA and RI/NPH are associated with longer survival among DM-related advanced HCC patients receiving sorafenib.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0244293</identifier><identifier>PMID: 33382703</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Biology and life sciences ; Carcinoma, Hepatocellular - complications ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - physiopathology ; Cohort Studies ; Comorbidity ; Diabetes ; Diabetes Complications - physiopathology ; Diabetes mellitus ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus - physiopathology ; Drug therapy ; Female ; Gastroenterology ; Growth factors ; Hepatocellular carcinoma ; Hepatology ; Hepatoma ; Hospitals ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - physiopathology ; Inhibitor drugs ; Insulin ; Internal medicine ; Liver cancer ; Liver Neoplasms - complications ; Liver Neoplasms - physiopathology ; Male ; Medical prognosis ; Medicine ; Medicine and Health Sciences ; Metastasis ; Metformin ; Metformin - therapeutic use ; Middle Aged ; Patients ; Physical Sciences ; Prognosis ; Protamine sulfate ; Research and Analysis Methods ; Retrospective Studies ; Sorafenib - therapeutic use ; Survival ; Survival analysis ; Taiwan - epidemiology ; Targeted cancer therapy ; Tumors</subject><ispartof>PloS one, 2020-12, Vol.15 (12), p.e0244293-e0244293</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Hsieh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Hsieh et al 2020 Hsieh et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-870fec631b8484dc751d961c33ace6cc61fae1a393f1257e32f4fe7fab2c572a3</citedby><cites>FETCH-LOGICAL-c692t-870fec631b8484dc751d961c33ace6cc61fae1a393f1257e32f4fe7fab2c572a3</cites><orcidid>0000-0001-9751-6692</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775090/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775090/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33382703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Yu, Ming-Lung</contributor><creatorcontrib>Hsieh, Ming-Han</creatorcontrib><creatorcontrib>Kao, Tzu-Yu</creatorcontrib><creatorcontrib>Hsieh, Ting-Hui</creatorcontrib><creatorcontrib>Kao, Chun-Chi</creatorcontrib><creatorcontrib>Peng, Cheng-Yuan</creatorcontrib><creatorcontrib>Lai, Hsueh-Chou</creatorcontrib><creatorcontrib>Chuang, Po-Heng</creatorcontrib><creatorcontrib>Kao, Jung-Ta</creatorcontrib><title>Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib.
From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to the presence/absence of DM or HTN, they were divided into four groups: control [DM(-)/HTN(-), n = 353], DM-only [DM(+)/HTN(-), n = 91], HTN-only [DM(-)/HTN(+), n = 184] and DM+HTN groups [DM(+)/HTN(+), n = 105]. Based on the types of diabetes medications, there were three groups among DM patients (the combined cohort of DM-only and DM+HTN groups), including metformin (n = 63), non-metformin oral hypoglycemic agent (OHA) (n = 104) and regular insulin (RI)/neutral protamine hagedorn (NPH) groups (n = 29). We then assessed the survival differences between these groups.
DM-only and DM+HTN groups significantly presented longer overall survival (OS) than control group (control vs. DM-only, 7.70 vs. 11.83 months, p = 0.003; control vs. DM+HTN, 7.70 vs. 11.43 months, p = 0.008). However, there was no significant OS difference between control and HTN-only group (7.70 vs. 8.80 months, p = 0.111). Besides, all groups of DM patients showed significantly longer OS than control group (control vs. metformin, 7.70 vs. 12.60 months, p = 0.011; control vs. non-metformin OHA, 7.70 vs. 10.80 months, p = 0.016; control vs. RI/NPH, 7.70 vs. 15.20 months, p = 0.026).
Rather than HTN, DM predicts better prognosis in advanced HCC treated with sorafenib. Besides, metformin, non-metformin OHA and RI/NPH are associated with longer survival among DM-related advanced HCC patients receiving sorafenib.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biology and life sciences</subject><subject>Carcinoma, Hepatocellular - complications</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - physiopathology</subject><subject>Cohort Studies</subject><subject>Comorbidity</subject><subject>Diabetes</subject><subject>Diabetes Complications - physiopathology</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus - physiopathology</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Growth factors</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatology</subject><subject>Hepatoma</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - complications</subject><subject>Hypertension - physiopathology</subject><subject>Inhibitor drugs</subject><subject>Insulin</subject><subject>Internal medicine</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - complications</subject><subject>Liver Neoplasms - physiopathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Metastasis</subject><subject>Metformin</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Physical Sciences</subject><subject>Prognosis</subject><subject>Protamine sulfate</subject><subject>Research and Analysis Methods</subject><subject>Retrospective Studies</subject><subject>Sorafenib - therapeutic use</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Taiwan - epidemiology</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk01v1DAQhiMEoqXwDxBEQkJw2MWOnTi5IFUVHytVKuLrak2c8a6rxN7aTqH_Hi-bVhvUA_LBlueZ157Xnix7TsmSMkHfXbrRW-iXW2dxSQrOi4Y9yI5pw4pFVRD28GB9lD0J4ZKQktVV9Tg7YozVhSDsOPNfvFtbF6JRuXc9htzpvDPQYkzrAfvexDHkYLt8c7NFH9EG42xubA7dNViFKYBbiE4lduzB5wq8MtYNkEePEBPwy8RNHpwHjda0T7NHGvqAz6b5JPvx8cP3s8-L84tPq7PT84WqmiIuakE0qorRtuY175QoaddUVDEGCiulKqoBKbCGaVqUAlmhuUahoS1UKQpgJ9nLve62d0FOdgVZcMF51ZQlS8RqT3QOLuXWmwH8jXRg5N8N59cSfHKmR0lUodsWtKqQc1DJWSQ1IwgN5VUJmLTeT6eN7YCdQhs99DPRecSajVy7aymEKElDksCbScC7qxFDlIMJO1PBohv39y4JobxO6Kt_0Purm6g1pAKM1S6dq3ai8rTigpaCEZqo5T1UGh0ORqW_pU3anyW8nSUkJuLvuIYxBLn69vX_2Yufc_b1AbtB6OMmuH6M6buFOcj3oPIuBI_6zmRK5K41bt2Qu9aQU2uktBeHD3SXdNsL7A_TWwvQ</recordid><startdate>20201231</startdate><enddate>20201231</enddate><creator>Hsieh, Ming-Han</creator><creator>Kao, Tzu-Yu</creator><creator>Hsieh, Ting-Hui</creator><creator>Kao, Chun-Chi</creator><creator>Peng, Cheng-Yuan</creator><creator>Lai, Hsueh-Chou</creator><creator>Chuang, Po-Heng</creator><creator>Kao, Jung-Ta</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9751-6692</orcidid></search><sort><creationdate>20201231</creationdate><title>Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib</title><author>Hsieh, Ming-Han ; Kao, Tzu-Yu ; Hsieh, Ting-Hui ; Kao, Chun-Chi ; Peng, Cheng-Yuan ; Lai, Hsueh-Chou ; Chuang, Po-Heng ; Kao, Jung-Ta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-870fec631b8484dc751d961c33ace6cc61fae1a393f1257e32f4fe7fab2c572a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biology and life sciences</topic><topic>Carcinoma, Hepatocellular - complications</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - physiopathology</topic><topic>Cohort Studies</topic><topic>Comorbidity</topic><topic>Diabetes</topic><topic>Diabetes Complications - physiopathology</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus - physiopathology</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Growth factors</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatology</topic><topic>Hepatoma</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - complications</topic><topic>Hypertension - physiopathology</topic><topic>Inhibitor drugs</topic><topic>Insulin</topic><topic>Internal medicine</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - complications</topic><topic>Liver Neoplasms - physiopathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Metastasis</topic><topic>Metformin</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Physical Sciences</topic><topic>Prognosis</topic><topic>Protamine sulfate</topic><topic>Research and Analysis Methods</topic><topic>Retrospective Studies</topic><topic>Sorafenib - therapeutic use</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Taiwan - epidemiology</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsieh, Ming-Han</creatorcontrib><creatorcontrib>Kao, Tzu-Yu</creatorcontrib><creatorcontrib>Hsieh, Ting-Hui</creatorcontrib><creatorcontrib>Kao, Chun-Chi</creatorcontrib><creatorcontrib>Peng, Cheng-Yuan</creatorcontrib><creatorcontrib>Lai, Hsueh-Chou</creatorcontrib><creatorcontrib>Chuang, Po-Heng</creatorcontrib><creatorcontrib>Kao, Jung-Ta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints Resource Center</collection><collection>Science in Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsieh, Ming-Han</au><au>Kao, Tzu-Yu</au><au>Hsieh, Ting-Hui</au><au>Kao, Chun-Chi</au><au>Peng, Cheng-Yuan</au><au>Lai, Hsueh-Chou</au><au>Chuang, Po-Heng</au><au>Kao, Jung-Ta</au><au>Yu, Ming-Lung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-12-31</date><risdate>2020</risdate><volume>15</volume><issue>12</issue><spage>e0244293</spage><epage>e0244293</epage><pages>e0244293-e0244293</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib.
From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to the presence/absence of DM or HTN, they were divided into four groups: control [DM(-)/HTN(-), n = 353], DM-only [DM(+)/HTN(-), n = 91], HTN-only [DM(-)/HTN(+), n = 184] and DM+HTN groups [DM(+)/HTN(+), n = 105]. Based on the types of diabetes medications, there were three groups among DM patients (the combined cohort of DM-only and DM+HTN groups), including metformin (n = 63), non-metformin oral hypoglycemic agent (OHA) (n = 104) and regular insulin (RI)/neutral protamine hagedorn (NPH) groups (n = 29). We then assessed the survival differences between these groups.
DM-only and DM+HTN groups significantly presented longer overall survival (OS) than control group (control vs. DM-only, 7.70 vs. 11.83 months, p = 0.003; control vs. DM+HTN, 7.70 vs. 11.43 months, p = 0.008). However, there was no significant OS difference between control and HTN-only group (7.70 vs. 8.80 months, p = 0.111). Besides, all groups of DM patients showed significantly longer OS than control group (control vs. metformin, 7.70 vs. 12.60 months, p = 0.011; control vs. non-metformin OHA, 7.70 vs. 10.80 months, p = 0.016; control vs. RI/NPH, 7.70 vs. 15.20 months, p = 0.026).
Rather than HTN, DM predicts better prognosis in advanced HCC treated with sorafenib. Besides, metformin, non-metformin OHA and RI/NPH are associated with longer survival among DM-related advanced HCC patients receiving sorafenib.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33382703</pmid><doi>10.1371/journal.pone.0244293</doi><tpages>e0244293</tpages><orcidid>https://orcid.org/0000-0001-9751-6692</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-12, Vol.15 (12), p.e0244293-e0244293 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2474469553 |
| source | PubMed Central Free; MEDLINE; Public Library of Science; DOAJ Directory of Open Access Journals; Free Full-Text Journals in Chemistry; EZB Electronic Journals Library |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biology and life sciences Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - physiopathology Cohort Studies Comorbidity Diabetes Diabetes Complications - physiopathology Diabetes mellitus Diabetes Mellitus - drug therapy Diabetes Mellitus - physiopathology Drug therapy Female Gastroenterology Growth factors Hepatocellular carcinoma Hepatology Hepatoma Hospitals Humans Hypertension Hypertension - complications Hypertension - physiopathology Inhibitor drugs Insulin Internal medicine Liver cancer Liver Neoplasms - complications Liver Neoplasms - physiopathology Male Medical prognosis Medicine Medicine and Health Sciences Metastasis Metformin Metformin - therapeutic use Middle Aged Patients Physical Sciences Prognosis Protamine sulfate Research and Analysis Methods Retrospective Studies Sorafenib - therapeutic use Survival Survival analysis Taiwan - epidemiology Targeted cancer therapy Tumors |
| title | Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T17%3A18%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20roles%20of%20diabetes%20mellitus%20and%20hypertension%20in%20advanced%20hepatocellular%20carcinoma%20treated%20with%20sorafenib&rft.jtitle=PloS%20one&rft.au=Hsieh,%20Ming-Han&rft.date=2020-12-31&rft.volume=15&rft.issue=12&rft.spage=e0244293&rft.epage=e0244293&rft.pages=e0244293-e0244293&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0244293&rft_dat=%3Cgale_plos_%3EA647157301%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2474469553&rft_id=info:pmid/33382703&rft_galeid=A647157301&rft_doaj_id=oai_doaj_org_article_0c2fbbafc6e44ac193e0830ea91465ae&rfr_iscdi=true |